Objective: This study aimed to investigate the clinical outcomes and mortality risk factors associated with alcohol use disorder (AUD) in hospitalized COVID-19 patients.
Methods: We analyzed a national database containing information on the clinical and sociodemographic aspects of patients hospitalized with severe acute respiratory syndrome between February 2020 and February 2023 in Brazil, including those aged > 18 years with laboratory-confirmed COVID-19. The primary exposure of interest was a history of AUD before admission and the primary outcome was in-hospital mortality.
Results: Among the 2,124,285 patients, 11,433 (0.53 %) had AUD. The in-hospital mortality rate was higher in the patients with AUD (46.2%) than in those without AUD (31.9%). After adjusting for confounding covariates, individuals with AUD had twice the risk of death (Odds Ratio [OR]= 1.94, 95% confidence interval [CI] 1.85-2.03) compared with non-AUD patients. Among individuals with AUD, the covariates independently associated with the primary outcome were age > 60 years, male sex, hospitalization in the Central-West, Northeast and North regions, symptoms of dyspnea and reduced oxygen saturation at admission, presence of comorbidities, and year of admission.
Conclusion: In this population-based study, we found that patients with AUD had twice the risk of fatal outcomes than those without AUD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.47626/2237-6089-2024-1028 | DOI Listing |
Alcohol Clin Exp Res (Hoboken)
March 2025
Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Background: Alcohol-related liver disease (ARLD) is a leading cause of preventable death and health inequalities. Evidence-based interventions for comorbid alcohol use disorder (AUD) and ARLD remain limited, and only a small proportion of this clinical population engages with treatment. There is a need to improve patient outcomes by bridging this gap through novel, person-centred interventions.
View Article and Find Full Text PDFPhys Chem Chem Phys
March 2025
Computational Chemistry Research Laboratory (CCRL), Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur-603 203, Chengalpattu, Tamil Nadu, India.
This study explores how an active pharmaceutical ingredient-ionic liquid (API-IL), cholinium taurate ([Cho][Tau]) IL, may alter the structural and functional stability of histone deacetylase 2 (HDAC2), which is a crucial enzyme linked to alcohol use disorder (AUD). A particular hallmark of AUD, which is a worldwide health burden, is epigenetic dysregulation, in which HDAC2 plays a significant role in gene silencing and chronic neuroplastic alterations. Leveraging the unique physicochemical properties of [Cho][Tau]IL, including hydrogen bond (H-bond) formation and structural reinforcement, we explored its therapeutic potential through comprehensive computational approaches.
View Article and Find Full Text PDFUnlabelled: is a commensal yeast that is a common component of the gastrointestinal (GI) microbiome of humans. has been shown to bloom in the GI tract of individuals with alcohol use disorder (AUD) and can promote and increase the severity of alcoholic liver disease (ALD). However, the effects of blooms on the host in the context of AUD or AUD-related phenotypes, such as ethanol preference, have been unstudied.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!